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 Abstract - Meniere's disease (MD) is an idiopathic inner 
ear disorder characterized by spontaneous recurrent 
vertigo, fluctuating sensorineural hearing loss (SNHL), 
aural fullness and tinnitus. Endolymphatic hydrops (EH) 
of the inner ear is currently considered the 
pathophysiological mechanisms that underlies typical 
symptoms of MD. MD diagnosis is based on the criteria of 
the Baràny Society. There are many therapeutic options 
for MD, but none is considered effective by the scientific 
community. The first-line treatment commonly includes 
dietary modification, as low salt diet and reduction of 
alcohol and caffeine daily intake. 
Although some studies showed a positive effect of 
these dietary restrictions, even in the prevention of 
recurrences, currently there is no uniform consensus on 
their usefulness. 
New dietary approach, such SPC-flakes, are being 
evaluated: further assessments will be needed to validate 
their use in clinical practice. 
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I.  INTRODUCTION 
 
 Meniere's disease (MD) is an idiopathic inner ear 
disorder, first described by Prosper Meniere in 1861, 
characterized by spontaneous recurrent vertigo, 
fluctuating sensorineural hearing loss (SNHL), aural 
fullness and tinnitus [1,2,3]. The main clinical aspect in 
MD is the recurrence of sudden and unexpected vertigo 
attacks that are often debilitating and may severely affect 
quality of life [4,5]. 
Endolymphatic hydrops (EH) of the inner ear is currently 
considered the pathophysiological mechanisms that 
underlies typical symptoms of MD. EH seems to be due to 
an overproduction of endolymph and/or a decrease in the 














Fig. 1.  Examples of two labyrinths, one normal and the other with 
endolymphatic hydrops (EH). EH is a pathological condition in which 
there is a distention of endolymphatic space by enlargement of 
endolymphatic volume. From Nakashima et al [3]. 
 
 
MD diagnosis is based on the criteria of the Baràny 
Society [6].  
There are many therapeutic options for MD, but none is 
considered effective by the scientific community [7] 
[Table 1].
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Table 1.  First-line and second-line therapy for Meniere's disease.  
 
The first-line treatment commonly includes dietary 
modification such as restriction of salt, caffeine, alcohol 
intake and several drugs [8,9]. 
Concerning the current opinions about which should 
represent the better dietary management in patients 
affected by MD, we want to underline the lack of mention 
about glucose daily intake. 
In a recent review from our group, we remarked the 
possible role played by hyperinsulinemia in subjects 
affected by MD [10].  
We know that the saccule, the main labyrinthine structure 
affected by pathological damage due to the endolymphatic 
hydrops, has a large numbers of insulin receptors. This 
observation was confirmed by the examination of 
cadaveric subjects and in vivo analysis by cervical 
Vestibular Evoked Myogenic Potentials (cVEMPs) [11]. 
Based on this evidence, we suggest to pay special 
attention in the evaluation of MD patients who present 
hyperinsulinemia anticipating a MD crisis. So,  we think 
that it is important to define the correct daily intake for 
patient with MD to reduce recurrences. 
In order to prevent crisis, we observed that patients with 
unilateral MD treated with specially processed cereals that 
increase endogenous antisecretory factor synthesis 
compared to patients treated with intravenous glycerol and 
dexamethasone, showed a reduced number of vertigo 
attacks and a positive effect on the discomfort generate by 
tinnitus and quality of life [12]. 
Several drugs have been proposed for the treatment of MD 
both for acute attacks (dimenhydrinate, benzodiazepines), 
and as a prophylactic therapy (betahistine, βblockers, 
diuretics), although evidence of their efficacy is lacking 
[3]. 
When  first-line treatment does not offer a satisfactory 
symptom control, especially for vertigo, more invasive 
treatments classified into conservative and ablative are 
recommended [7].  Intratympanic (IT) administration of 
corticosteroids or gentamicin is commonly used [13,14]. 
Corticosteroids have been shown to have a lower risk of 
hearing damage [15,16] but less efficacy in vertigo attack 
control compared to gentamicin [17,18].  
Gentamicin, administered in different doses and timing, 
has been proven as an effective treatment for vertigo in 
MD with a potential risk of hearing loss [19,20,21,22]. 
Controversy remains about the gentamicin dosage and 
method used . Some physicians favor the use of low-dose 
gentamicin in which the drug is injected once and further 
treatments are only performed in cases of recurrent vertigo 
attacks; other authors prefer high-dose gentamicin, 
titration or continuous administration in which the drug is 
injected until vestibular weakness is reached 
[23,24,25,26,27,28,29,30,31].  
However, hearing loss and healthy-side vestibular 
hypofunction after IT gentamicin administration still 
represent potential risks of this treatment due to its 
ablative nature and ototoxicity [32].  
Other studies demonstrated that low-dose intratympanic 
gentamicin can produce a satisfactory control of vertigo 
attacks after treatment with limited risk of hearing loss 
[33]. 
There are some patients with frequent vertigo attacks, 
progressive hearing loss and persistent annoying tinnitus 
even through the continuous standard medical treatments; 
this is called “intractable Meniere’s disease [34]. 
The consensus is that management of Meniere’s disease 
should follow a therapeutic escalation from non-invasive 
medical treatment to surgical treatment that may involve 
ablation.  
Surgery is not to be considered without audiometric and 
imaging assessment: before considering ablation, ipsi- and 
controlateral vestibular function should be assessed [35]. 
Invasive procedures such as vestibular nerve section or 
labyrinthectomy may be suggested in case of treatment 
failure. 
Recently, an electronic questionnaire formulated by a 
work group leaded Quaranta and sent to Italian 
otolaryngologists, showed that in Italy, refractory case of 
MD are treated initially with IT steroids and, therefore, 
with gentamicin; in case of failure of IT treatment, 
vestibular nerve section is the treatment of choice 
[36,37,38,39,40,41]. 
In this review article, we would like to consider the 




II.  DIETARY RESTRICTION FOR THE TREATMENT 
OF MENIERE’S DISEASE 
 
There is no consensus about the first line medical 
treatment of Meniere’s disease to produce symptomatic 
improvement and slow the disease progress. Dietary 
restrictions is among the first line treatment that has been 
proposed for long. They include low salt diet, 
abundant water intake, moderate alcohol and caffeine 
  First-line 
Treatment 
Dietary modification Drugs administration 
 Low salt diet Diuretics 
 Abundant water intake Steroids 
 Alcohol and caffeine 
consumption 
Bethaistine 
 Gluten-free diet Dimenhydrinate 
 Specially processed 
cereals 
Benzodiazepines 






 Intratympanic steroids Intratympanic 
gentamicin 
 Endolymphatic sac 
surgery 
Vestibular neurectomy 
 Pressure pulse treatment Labyrinthectomy 
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consumption, gluten-free diet, intake of specially 
processed cereals (SPC-flakes). 
 
 
A. Low salt diet 
 
Low salt diet is widely used as a first line treatment 
option. Daily sodium intake is recommended to be under 
2000 mg. The low salt intake is believed to be helpful in 
lowering endolymphatic pressure; however, this is already 
to prove [42].  
Luxford E. et al. found an improvement in the number and 
severity of vertigo with dietary modification containing 
low sodium diet [43]. Beneficial result of dietary sodium 
restriction has also been documented by Sheahan SL. et al. 
[44]. 
 Dietary sodium restriction has been advised by many 
clinicians as a first line treatment for Meniere disease 
[45]. Also Miyashita et al [46] suggested that low-salt diet 
should be an effective first line of treatment for patients 
withe MD; in authors’s opinion, this treatment will have a 
greater effect, when sodium intake is reduced to less than 
3 g/day, due to an increase in the plasma aldosterone 
concentration that can activate ion transport and absorbing 
endolymph in the endolymphatic sac.  
In a study by Acharya et al. there is no evidence of benefit 
by dietary salt restriction in terms of hearing 
improvement, number of vertigo, severity of vertigo and 
tinnitus score [47]. 
De Ru and Heerens suggested that it is not sodium that 
should be avoided but potassium [48]. 
However, strong evidence that salt restriction is beneficial 
does not exist. 
 
B. Abundant water intake 
 
Naganuma et al [49] proposed time-series study with 
historical control regarding the water intake therapy for 
patients with MD that demonstrates that water intake 
therapy could improve and prevent hearing loss compared 
to other conventional therapies. 
Hearing ability and relieved vertigo are improved in these 
patients by the increased drinking water and decrease of 
plasma ADH level. 
A group leaded by Kitahara [50] confirmed that abundant 
water intake (35 mL/Kg/day as specified by Naganuma) 
can be a feasible treatment in Meniere’s disease. 
 
 
C. Alcohol and caffeine consumption 
 
Regarding alcohol, many clinicians recommend to avoid 
or reduce its consumption. A recent work by Sanchez-
Sellero et al [51] evaluated the possibility that alcohol 
consumption delays the age at onset of Menière’s disease; 
the authors explained this by the inhibitory effect of 
alcohol on hypothalamic production of vasopressin: a 
lower release of this neurormone increases diuresis while 
decreasing endolymphatic pressure. 
However, actually the literature doesn’t offer review to 
evaluate if alcohol consumption is more prevalent or more 
intense in patients with MD. 
Another substance highly considered in the preventive 
treatment of MD is caffeine, an alkaloid present in many 
foods and as an additive in “cola-type” drinks and “energy 
drinks”. 
Pharmacological effect of caffein might include 
antagonistic effects on adenosine receptors, renal effects 
as diuresis and natriuresis, activation of renin-angiotensin-
aldosterone system, release of corticosteroids by adrenal 
cortes and catecholamines drama adrenal medulla [52]. 
Also Sanchez-Sellero [53] observed that caffeine should 
be considered as a precipitating factor for the onset of 
symptoms in people predisposed to developing Menière’s 
disease. The authors suggested that it should be 
recommended to reduce caffeine intake in those 
population groups with higher risk of Menière’s disease. 
 
D. Gluten-free diet 
 
Recently other possible dietary modifications have been 
linked to Meniere’s disease’s treatment. 
Di Berardino et al [54] reported a case of remitted 
unilateral Meniere disease after 6 months of a restrictive 
gluten-free diet. The same authors were the first to report 
a gliadin skin test in 33 patients with definite MD [55] and 
the first to observed an altered intestinal permeability in 
symptomatic MD patients.  
Further studies will be necessary to assess if the 
investigation of intestinal permeability and fecal 
calprotectin can be added to the current clinical practice, 
aimed at identifying those MD patients who would benefit 
from deprivation diets. 
 
E. Specially processed cereals (SPC) 
 
Recently, the intake of antisecretory factor (AF)-inducing 
specially processed cereals (SPC)-flakes has been 
proposed as complementary therapy for Meniere’s 
disease.  
Antisecretory factor (AF) is a 41 kDa protein originally 
isolated due to its ability to inhibit experimental diarrhoea; 
the specific effect of endogenous AF is not completely 
understood, but it seems to modulate water and ion 
transport. 
The intake of specially processed cereals (SPC-flakes) 
results in an increase of AF activity in plasma [56]. 
Hanner et al hypothesized that an increased AF activity 
could positively influence the course of MD: their work 
demonstrated that the intake of SPC-flakes not only 
significantly reduced vertigo in a half of the patients, but 
was also related to an increase level of active AF in 
plasma and positive clinical outcome. 
Treatment with SPC appears to be well tolerated by most 
patients [57] without any complications and, in most of 
studies, more than half of the study cohort reported 
subjective improvement in functional level. 
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On the contrary, Ingvardsen and Klokker [58] observed 
that antisecretory factor-inducing (AF) SPC were not 
shown to significantly improve the functional level in 
patients with MD. 
 
 
III.  CONCLUSION 
 
Many clinicians recommend to reduce the intake of salt, 
caffeine and alcohol for the therapy of Meniere’s disease. 
Although some studies showed a positive effect of dietary 
restrictions, even in the prevention of recurrences, 
currently there is no uniform consensus on their 
usefulness. 
New dietary approach, such SPC-flakes, are being 
evaluated: further assessments will be needed to validate 
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